Funding Opportunity PAR-18-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Negotiable: Paramount Recruitment: Director of Bioinformatics & Computational Biology Genomics, Leadership, Target Discovery, NGS, Research Department A fantastic new Director level position has become available with a Top research-driven pharmaceutical company in South-West Germany. Biberach an der Riß, Germany

Negotiable: Paramount Recruitment: Commercial Partnerships Manager Bioinformatics, Genomics, Central London - 100,000 Genomes Project - Commercial Division! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Geno London, England

Notice NOT-TW-18-002 from the NIH Guide for Grants and Contracts

Notice NOT-TW-18-001 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-18-351 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage applications that seek to conduct studies of the visual system. This FOA will support applications that either Those that involve human subjects, but are not NIH-defined clinical trials (see NOT-OD-15-015); or Those that are NIH-defined clinical trials and are designed to address either: 1) mechanisms underlying human vision in health and disease; or 2) interventions that entail procedures with minimal risk to subjects. A mechanistic trial is defined as "A study designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. "Minimal risk" means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. NIH-defined clinical trial applications that are neither mechanistic nor minimal risk are not eligible for this FOA. Large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials are not appropriate for this FOA. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.

Funding Opportunity RFA-NS-18-011 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical study to collect safety and effectiveness data required to support a marketing application or to inform final device design.

Funding Opportunity RFA-NS-18-012 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical study to collect safety and effectiveness data required to support a marketing application or to inform final device design.

Notice NOT-GM-18-005 from the NIH Guide for Grants and Contracts

The Bioinformatics Core will also interface with the Clinical Research Design, Epidemiology, & Biostatistics Core Facility in the WV Clinical and Translational...
From West Virginia University - Tue, 07 Nov 2017 22:55:28 GMT - View all Morgantown, WV jobs

Your application should include a letter of motivation, a complete CV, degrees, diplomas and reference letters....
From Hamilton Company - Tue, 07 Nov 2017 18:38:36 GMT - View all Home Based jobs

Funding Opportunity RFA-MH-18-510 from the NIH Guide for Grants and Contracts. The purpose of the BRAIN Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Applications are encouraged in any research area that is aligned with the BRAIN Initiative, including neuroethics. Applicants are expected to propose research training in an area that clearly complements their predoctoral research. Formal training in analytical tools appropriate for the proposed research is expected to be an integral component of the research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and who expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 12 months of postdoctoral training.

Funding Opportunity RFA-MH-18-610 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications to decipher pathways and mechanisms responsible for HIV-1 induced central nervous system (CNS) dysfunction seen in virally suppressed HIV-1 positive patients, by understanding the causal role played by altered neuronal circuits, neuronal receptors and neuronal networks. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Funding Opportunity RFA-MH-18-611 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications to decipher pathways and mechanisms responsible for HIV-1 induced central nervous system (CNS) dysfunction seen in virally suppressed HIV-1 positive patients, by understanding the causal role played by altered neuronal circuits, neuronal receptors and neuronal networks. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

And we will invest in the open-source R ecosystem in ways that help foster its evolution and add value to the data science community....
From Microsoft - Tue, 07 Nov 2017 16:14:57 GMT - View all Redmond, WA jobs

Notice NOT-TR-18-002 from the NIH Guide for Grants and Contracts

Notice NOT-TR-18-003 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-18-350 from the NIH Guide for Grants and Contracts. The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.

Funding Opportunity PAR-18-349 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career development (K18) awards that improve synergies among researchers in basic and applied behavioral-social sciences, human subjects and model animals settings; and biomedical and behavioral-social sciences.

Funding Opportunity PAR-18-208 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems.The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine.Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project.The goal of the program is to support projects that can realize meaningful solutions within 5 10 years.